Characterisation of a novel AmpC beta-lactamase, DHA-33, resistant to inhibition by cloxacillin

Diagn Microbiol Infect Dis. 2024 Aug;109(4):116356. doi: 10.1016/j.diagmicrobio.2024.116356. Epub 2024 May 20.

Abstract

Plasmid-encoded DHA-type AmpCs have been extensively reported in Enterobacterales. The expression of the genes encoding these plasmid-mediated enzymes are inducible and these enzymes are capable of conferring resistance to a wide spectrum of beta-lactams including penicillins and broad-spectrum cephalosporins. The identification of infections caused by AmpC-producing bacteria is a necessity, both for infection control/epidemiology purposes and to inform treatment choices. A common testing method for AmpC production in the clinical laboratory setting is to supplement Mueller-Hinton agar plates used for antibiotic disk diffusion with cloxacillin, a potent inhibitor of AmpC enzymes. Here we describe a novel DHA variant, produced by a clinical Escherichia coli isolate, which is resistant to cloxacillin inhibition.

Keywords: AmpC; Cloxacillin; DHA; Escherichia coli.

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • Bacterial Proteins* / genetics
  • Bacterial Proteins* / metabolism
  • Cloxacillin* / pharmacology
  • Escherichia coli Infections / drug therapy
  • Escherichia coli Infections / microbiology
  • Escherichia coli* / drug effects
  • Escherichia coli* / enzymology
  • Escherichia coli* / genetics
  • Humans
  • Microbial Sensitivity Tests*
  • beta-Lactamases* / genetics
  • beta-Lactamases* / metabolism

Substances

  • Cloxacillin
  • beta-Lactamases
  • AmpC beta-lactamases
  • Anti-Bacterial Agents
  • Bacterial Proteins